Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) EBIT (2020 - 2025)

Historic EBIT for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$18.5 million.

  • Foghorn Therapeutics' EBIT rose 2243.42% to -$18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.5 million, marking a year-over-year increase of 1692.02%. This contributed to the annual value of -$102.7 million for FY2024, which is 484.03% up from last year.
  • As of Q3 2025, Foghorn Therapeutics' EBIT stood at -$18.5 million, which was up 2243.42% from -$21.1 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' EBIT ranged from a high of -$17.1 million in Q3 2023 and a low of -$33.3 million during Q1 2023
  • For the 5-year period, Foghorn Therapeutics' EBIT averaged around -$25.8 million, with its median value being -$26.3 million (2021).
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 6853.69% in 2021, then surged by 3955.55% in 2023.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' EBIT stood at -$28.1 million in 2021, then dropped by 13.55% to -$31.9 million in 2022, then grew by 20.16% to -$25.5 million in 2023, then increased by 5.71% to -$24.0 million in 2024, then rose by 22.93% to -$18.5 million in 2025.
  • Its EBIT stands at -$18.5 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$22.9 million for Q1 2025.